一种免疫抑制抗体-药物结合剂
Rongsheng E Wang1, Tao Liu, Ying Wang
1Department of Chemistry and the Skaggs Institute for Chemical Biology and ‡Department of Immunology and Microbial Science, The Scripps Research Institute , La Jolla, California 92037, United States.
一种新的抗体 - 药物结合物 (ADC) 选择性地用达沙提尼布向T淋巴细胞,抑制T细胞激活. 这种新的方法提供了一种潜在的新型免疫抑制药物类别,具有增强的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 抗体与药物联合体 (ADC) 提供有针对性的药物输送.
- T淋巴细胞在免疫反应中起着至关重要的作用.
- CXCR4是一种细胞表面受体,在造血细胞上表达.
研究的目的:
- 开发一种新的ADC,用于选择性地将Lck抑制剂达沙替尼布输送到人类T淋巴细胞.
- 评估ADC在抑制T细胞激活和细胞因子表达方面的有效性.
- 探索这种ADC策略在开发新免疫抑制疗法方面的潜力.
主要方法:
- 开发一种针对CXCR4的人性化抗体.
- 抗体与达沙替尼布的结合产生ADC.
- 评估T细胞激活,细胞因子表达和细胞活性的反应ADC.
主要成果:
- 开发出来的ADC在T淋巴细胞上选择性地与CXCR4结合.
- 该ADC有效地抑制T细胞受体 (TCR) 介导的T细胞激活和细胞因子表达.
- 结合物表现出强烈的活性,nM EC50低,对细胞活力影响最小.
结论:
- 一种新型的ADC使得达沙替尼能够有针对性地向T淋巴细胞输送达沙替尼.
- 这种ADC代表了一种有希望的选择性免疫抑制的新策略.
- 可以将ADC方法扩展到非瘤学指示中酶抑制剂的向输送.
更多相关视频
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunocytochemistry and Immunohistochemistry
These...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Drug Products: Biologics, Biosimilars and Interchangeables
Immunoprecipitation
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
